JP
Revvity Sites Globally
Select your location.
*e-commerce not available for this region.
Application Note
Unlock your STING polymorphism research with a comprehensive HTRF binding platform
STING protein is a mediator of innate immunity and a candidate for auto immune disease or cancer immunotherapy. Clinical trials are already ongoing, and targeting all STING variants has become crucial. R232 is the most common variant, and HAQ and H232 alleles are also present in the human population.
To help progress your research in identifying and charaterizing potential universal new STING therapeutics, Revvity has developed this note with:
- How HTRF human and mouse STING assays are built up.
- What their main features are.
- How the most relevant and promising STING agonists, like ADU-S100, behave towards the different STING variants.
For research use only. Not for use in diagnostic procedures.
To view the full content please answer a few questions
Download Resource
Unlock your STING polymorphism research with a comprehensive HTRF binding platform